SG11202002882VA - Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents - Google Patents

Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Info

Publication number
SG11202002882VA
SG11202002882VA SG11202002882VA SG11202002882VA SG11202002882VA SG 11202002882V A SG11202002882V A SG 11202002882VA SG 11202002882V A SG11202002882V A SG 11202002882VA SG 11202002882V A SG11202002882V A SG 11202002882VA SG 11202002882V A SG11202002882V A SG 11202002882VA
Authority
SG
Singapore
Prior art keywords
radiotherapy
imaging agents
evans blue
chemical conjugates
blue derivatives
Prior art date
Application number
SG11202002882VA
Inventor
Xiaoyuan Chen
Weiss Orit Jacobson
Original Assignee
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America As Represented By The Secretary filed Critical The United States Of America As Represented By The Secretary
Publication of SG11202002882VA publication Critical patent/SG11202002882VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
SG11202002882VA 2017-10-03 2017-10-03 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents SG11202002882VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/054863 WO2019070236A1 (en) 2017-10-03 2017-10-03 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Publications (1)

Publication Number Publication Date
SG11202002882VA true SG11202002882VA (en) 2020-04-29

Family

ID=65994901

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002882VA SG11202002882VA (en) 2017-10-03 2017-10-03 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Country Status (6)

Country Link
US (1) US10981866B2 (en)
EP (1) EP3692032A4 (en)
JP (1) JP7097436B2 (en)
CN (1) CN111542518B (en)
SG (1) SG11202002882VA (en)
WO (1) WO2019070236A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709790B2 (en) 2015-06-22 2020-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
US10696631B2 (en) 2016-05-09 2020-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
EP3755321A4 (en) * 2018-02-22 2021-11-24 The United States of America, as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
CN117120428A (en) * 2021-02-10 2023-11-24 烟台蓝纳成生物技术有限公司 Truncated Evan blue modified fibroblast activation protein inhibitor and preparation method and application thereof
CN114369084B (en) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof
WO2023202730A2 (en) * 2022-04-20 2023-10-26 北京先通国际医药科技股份有限公司 Radioactive evans blue derivative pharmaceutical aqueous solution, preparation method therefor, and use thereof
CN114748471A (en) * 2022-04-20 2022-07-15 北京先通国际医药科技股份有限公司 Preparation method and application of radiolabeled Evans blue derivative drug
CN114796532A (en) * 2022-04-20 2022-07-29 北京先通国际医药科技股份有限公司 Radiolabeled evans blue derivative drug aqueous solution and application thereof
CN115947775B (en) * 2023-03-13 2023-06-09 北京先通国际医药科技股份有限公司 Method for preparing compound (I), compound (I) and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4569875B2 (en) 2003-02-27 2010-10-27 国立大学法人九州大学 Contrast agent for MRI
WO2006025304A1 (en) * 2004-08-30 2006-03-09 Kyushu University, National University Corporation Mri contrast agent for arteriosclerosis detection
US20160045626A1 (en) 2007-01-11 2016-02-18 Immunomedics, Inc. Methods and Compositions for Improved Labeling of Targeting Peptides
WO2009038660A1 (en) 2007-09-14 2009-03-26 Health Research, Inc. Multimodality agents for tumor imaging and therapy
US10556873B2 (en) 2008-02-22 2020-02-11 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
JP5677096B2 (en) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー Methods for preventing and treating acute kidney injury
CN103242255B (en) 2013-04-28 2015-01-14 厦门大学 Evans blue complex as well as preparation method and application thereof
CN104650217B (en) * 2015-01-26 2018-08-10 莎穆(上海)生物科技有限公司 The Exendin-4 and its preparation method and application of Azo-Blue or derivatives thereof modification
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
US10709790B2 (en) 2015-06-22 2020-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
US20190298824A1 (en) 2016-05-04 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Albumin-binding immunomodulatory compositions and methods of use thereof
US10696631B2 (en) 2016-05-09 2020-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
CN107629016B (en) 2017-11-12 2020-05-22 莎穆(上海)生物科技有限公司 Evans blue complex and preparation method and application thereof
EP3755321A4 (en) 2018-02-22 2021-11-24 The United States of America, as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
US20220017495A1 (en) 2019-01-30 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Conjugates of bivalent evans blue dye derivatives and methods of use

Also Published As

Publication number Publication date
EP3692032A4 (en) 2021-04-07
EP3692032A1 (en) 2020-08-12
US10981866B2 (en) 2021-04-20
JP7097436B2 (en) 2022-07-07
JP2021503439A (en) 2021-02-12
CN111542518B (en) 2023-10-10
US20200231543A1 (en) 2020-07-23
WO2019070236A1 (en) 2019-04-11
CN111542518A (en) 2020-08-14

Similar Documents

Publication Publication Date Title
EP3455206A4 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
SG11202002882VA (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
IL276653A (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
IL280899A (en) Heterocyclic compounds for cancer imaging and treatment and methods for their use
IL248692B (en) Deuterated heterocyclic compounds and their use as imaging agents
HK1247630A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
IL259121B (en) Long-lived gadolinium based tumor targeted imaging and therapy agents
IL264176A (en) Methods and compositions for the treatment of cancer
EP3534969A4 (en) Formulations for radiotherapy and diagnostic imaging
IL263793A (en) Compounds and compositions for the treatment of cancer
IL257670A (en) Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
GB201617064D0 (en) Compounds and their therapeutic use
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
GB201715194D0 (en) Compounds and their therapeutic use
IL280587B (en) Flurocytidine derivatives and its composition for the treatment of cancer
IL271327A (en) Compositions and methods for enhancing hyperthermia therapy
IL283662A (en) Monomethyl fumarate-carrier conjugates and methods of their use
EP3157570C0 (en) Peptide-based compounds and their uses for tumor imaging and targeting
IL272147A (en) Methods and compositions for the treatment of cancer
EP3679046C0 (en) Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof
GB201610176D0 (en) Imaging agents and methods of use
GB201705679D0 (en) Imaging agent
IL274866A (en) Compositions and methods for cancer therapy
MX2020002812A (en) Abx196 for use in the treatment of bladder cancer.
GB201712049D0 (en) Novel compounds and their use